Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Blocking New Blood Vessel Formation Cures Alzheimer's Disease in Mouse Model

By BiotechDaily International staff writers
Posted on 21 Mar 2013
Print article
Vaccination of mice with a syndrome that mimics human Alzheimer's disease (AD) with amyloid-beta protein normalized the production of bloods vessels in the brains of the animals and eliminated the accumulation of amyloid plaque.

Investigators at the University of British Columbia (Vancouver, Canada) worked with the Tg2576 mouse AD model. In addition to the characteristic amyloid-beta (A-beta) plaques that characterize the brain in AD, these animals displayed an abnormal number of brain blood vessels. Some of these blood vessels were incomplete and caused leakiness in the blood-brain barrier (BBB).

The investigators immunized a group of Tg2576 mice with peptides derived from the amyloid-beta protein. They reported in the February 28, 2013, online edition of the journal Scientific Reports that immunization with A-beta peptides neutralized the amyloid trigger leading to formation of new blood vessels and reversed the abnormal number of these vessels in the Tg2576 AD mice. Reduction in number of blood vessels resolved the animals' plaque burden, suggesting that formation of new blood vessels (neoangiogenesis) was a key mechanism underlying plaque formation.

“The discovery provides further evidence of the role that an overabundance of brain blood vessels plays in AD, as well as the potential efficacy of amyloid-beta as basis for an AD vaccine,” said senior author Dr.Wilfred Jefferies, professor of medical genetics at the University of British Columbia. “Now that we know blood vessel growth is a factor in AD, if follows that drugs targeting blood vessels may be good candidates as an AD treatment.”

Related Links:
University of British Columbia



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.